Methods and compositions for preventing and treating auditory dysfunctions

US9457009B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9457009-B2
Application numberUS-201313907590-A
CountryUS
Kind codeB2
Filing dateMay 31, 2013
Priority dateMay 31, 2012
Publication dateOct 4, 2016
Grant dateOct 4, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of treating an auditory impairment associated with cochlear outer hair cell damage, dysfunction or loss in a subject comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester selected from the group consisting of: (a) 3,4-O-dicaffeoylquinic acid, (b) 3,5-O-dicaffeoylquinic acid, (c) 1,3-O-dicaffeoylquinic acid, (d) 4,5-O-dicaffeoylquinic acid, (e) 1,5-O-dicaffeoylquinic acid, (f) 3-O-feruloylquinic acid, (g) 4-O-feruloylquinic acid, (h) 5-O-feruloylquinic acid, (i) 1-O-caffeoylquinic acid, (j) 3-O-caffeoylquinic acid, (k) 4-O-caffeoylquinic acid, (l) 5-O-caffeoylquinic acid, (m) (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,4,5-trihydroxycyclohexanecarboxylic acid, (n) (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,4,5-trihydroxycyclohexanecarboxylic acid, (o) (1S,3R,4R,5R)-5-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,3,4-trihydroxycyclohexanecarboxylic acid, (p) (1S,3R,4R,5R)-5-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,3,4-trihydroxycyclohexanecarboxylic acid, (q) (1S,3R,4R,5R)-4-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,3,5-trihydroxycyclohexanecarboxylic acid, (r) (1S,3R,4R,5R)-4-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,3,5-trihydroxycyclohexanecarboxylic acid, (s) cis-5-O-caffeoylquinic acid, (t) 3-O-caffeoylquinic acid lactone, (u) 3-O-caffeoyl-4-O-feruloylquinic acid, and (v) a pharmaceutically acceptable salt thereof, so as to restore cochlear outer hair cell function, thereby treating the auditory impairment associated with cochlear outer hair cell damage, dysfunction or loss in the subject. 2. The method of claim 1 , wherein said composition further comprises an aqueous extract from Uncaria tomentosa bark. 3. The method of claim 1 , wherein the composition is formulated for administration selected from the group consisting of auricular, oral, parenteral, intraperitoneal, local, buccal, nasal, and topical administration. 4. The method of claim 1 , wherein said composition is an aqueous extract from Uncaria tomentosa bark. 5. The method of claim 1 , wherein said composition is in the form of a liquid, tablet or capsule. 6. The method of claim 1 , wherein the auditory impairment is selected from the group consisting of permanent sensorineural hearing loss, tinnitus, loudness recruitment, hyperacusis, diplacusis and speech intelligibility deficits. 7. The method of claim 1 , wherein the active agent is less than or equal to 10,000 daltons. 8. The method of claim 2 , wherein the aqueous extract from Uncaria tomentosa bark comprises an active agent of less than or equal to 10,000 daltons. 9. The method of claim 1 , wherein cochlear outer hair cell function is sensory function as assessed by audiological tests including distortion product otoacoustic emission (DPOAE).

Assignees

Inventors

Classifications

  • A61K31/216Primary

    of acids having aromatic rings, e.g. benactizyne, clofibrate · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • A61K31/365Primary

    Lactones · CPC title

  • of carboxylic acids · CPC title

  • Rubiaceae (Madder family) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9457009B2 cover?
The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acc…
Who is the assignee on this patent?
Guthrie O'Neil W, Us Veterans Affairs
What technology area does this patent fall under?
Primary CPC classification A61K31/216. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).